Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

MAIA says updated lung cancer data could support an accelerated approval filing

The small-cap biotech's ateganosine-plus-cemiplimab regimen controlled disease in 38 of 43 evaluable late-line lung cancer patients, but no filing or timeline has been announced.

17 Nov 2026 · MAIA Biotechnology, Inc. MAIA · Company news

MAIA Biotechnology is positioning its lung cancer combination for a possible shortcut to the US market. On 17 November 2026 the company said fresh Phase 2 data could support an application to the Food and Drug Administration under the agency's accelerated approval pathway. It has not announced a filing and has not given a submission date.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): MAIA Biotechnology, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →